PODD

NASDAQAfter Hours

Insulet Corporation

$288.73

$2.78 (-0.95%)

As of 10:31 AM

Open

$296.36

High

$299.47

Low

$287.52

Prev Close

$291.51

52W High

$354.88

52W Low

$230.05

Volume

956.69K

Mkt Cap

$20.31B

Overview News Chart Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation:.

zacks.com

4 Medical Device Stocks to Buy for Healthy Returns in 2026

ISRG, PODD, BSX and IDXX lead medtech innovation with AI, robotics and diagnostics for growth in 2026.

businesswire.com

Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod recycling program, which is now available to all U.S. customers. “Here at Insulet, our mission is to transform the lives of people with diabetes, and we are equally committed to creating a more sustainable future,” said Carolyn Sleeth, Senior Vice President and U.S. Ge.

defenseworld.net

Geneos Wealth Management Inc. Sells 3,253 Shares of Insulet Corporation $PODD

Geneos Wealth Management Inc. lowered its stake in shares of Insulet Corporation (NASDAQ: PODD) by 9.2% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,265 shares of the medical instruments supplier's stock after selling 3,253 shares during the

defenseworld.net

Frontier Capital Management Co. LLC Buys 2,683 Shares of Insulet Corporation $PODD

Frontier Capital Management Co. LLC boosted its stake in Insulet Corporation (NASDAQ: PODD) by 3.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,547 shares of the medical instruments supplier's stock after buying an additional 2,683 shares during the period. Frontier

zacks.com

Here is Why Growth Investors Should Buy Insulet (PODD) Now

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

zacks.com

PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements

Insulet Stock rises as the FDA clears key Omnipod 5 upgrades that enhance glucose targets and automation for its tubeless diabetes platform.

defenseworld.net

Insulet Corporation $PODD Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. cut its stake in Insulet Corporation (NASDAQ: PODD) by 20.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,112 shares of the medical instruments supplier's stock after selling 7,483 shares during the quarter. Brown Advisory Inc.'s

zacks.com

Here's Why Insulet (PODD) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

businesswire.com

Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new benchmark in tubeless diabetes technology by offering a lower 100 mg/dL Target Glucose option and a more seamless automated experie.

defenseworld.net

Fisher Asset Management LLC Trims Position in Insulet Corporation $PODD

Fisher Asset Management LLC decreased its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 27.8% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,519 shares of the medical instruments supplier's stock after selling 12,903 shares during the period. Fisher Asset Management LLC's

seekingalpha.com

Artisan International Small-Mid Fund Q3 2025 Contrarianism Pays Off

Our philosophy often runs counter to prevailing market sentiment, especially in times of excessive concentration and narrow market leadership. During this time, when many investors saw insulin pumps as “GLP-1 losers,” we acquired a position in Insulet (PODD) and added to our position in ConvaTec (CNVVY). We acquired shares of SolarEdge on the day the Trump administration began to review the Biden agenda.

zacks.com

Looking for a Growth Stock? 3 Reasons Why Insulet (PODD) is a Solid Choice

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

seekingalpha.com

Insulet Corporation (PODD) Analyst/Investor Day Transcript

Insulet Corporation ( PODD ) Analyst/Investor Day November 20, 2025 9:00 AM EST Company Participants Clare Trachtman - Vice President of Investor Relations Ashley McEvoy - CEO, President & Director Eric Benjamin - Executive VP & COO Trang Ly - Senior VP & Chief Medical Officer Manoj Raghunandanan - Senior VP & Chief Growth Officer Carolyn Sleeth - Senior Vice President of Global Commercial Capabilities & U.S. General Manager Flavia Pease - Executive VP & CFO Conference Call Participants Michael Conway Matthew O'Brien - Piper Sandler & Co., Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - BofA Securities, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Joanne Wuensch - Citigroup Inc., Research Division Danielle Antalffy - UBS Investment Bank, Research Division Michael Polark - Wolfe Research, LLC Christopher Pasquale - Nephron Research LLC Issie Kirby - Rothschild & Co Redburn, Research Division Joshua Jennings - TD Cowen, Research Division Presentation Clare Trachtman Vice President of Investor Relations Good morning, everyone, and welcome to Insulet's 2025 Investor Day.

businesswire.com

Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company's global headquarters in Acton, Massachusetts. During the event, Insulet's executive team outlined the strategic plan and innovation roadmap that is designed to extend its leadership in the fast-growing and significantly underpenetrated global markets for automa.

zacks.com